Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Akeso
QuantumLeap Healthcare Collaborative
Merck Sharp & Dohme LLC
University of Washington
H. Lee Moffitt Cancer Center and Research Institute
MedSIR
BioNTech SE
Japanese Foundation for Cancer Research
Merck Sharp & Dohme LLC